



## CONTINUED SALES GROWTH DRIVEN BY SUSTAINED ORGANIC GROWTH

April 22, 2010 (Lure, France) - Vétoquinol recorded a significant increase in sales in the first quarter of 2010, driven by sustained organic growth and the contribution of its Indian acquisition.

<i>In millions of euros</i>	<b>1<sup>st</sup> quarter 2010</b>	<b>1<sup>st</sup> quarter 2009</b>	<i>Percentage change</i>
Nominal revenue	<b>64.5</b>	<b>57.1</b>	+12.9%
at constant exchange rates	<b>63.0</b>	<b>57.1</b>	+10.4%
at constant exchange rates and business scope	<b>60.2</b>	<b>57.1</b>	+5.4%

Revenue for the first quarter of 2010 totalled €64.5 million: an increase of 12.9% over the same period in the preceding year. With exchange rates held constant, the increase was 10.4%. Vétoquinol benefited from a positive 2.5% exchange rate effect during this period, reflecting the strengthening of the Canadian dollar and the Polish zloty.

The energetic growth in the Group's sales in the 1<sup>st</sup> quarter was the result of strong organic growth, particularly in North America, where revenue increased by 16.8%. The Group benefited from the recovery in the American economy and from the successful U.S. launch of Surolan<sup>®</sup> in January.

The Group's recent acquisitions in Italy and India also contributed to sales growth in the first quarter of 2010.

Sales in the Group's three strategic therapeutic domains – anti-infectives, pain-inflammation, and cardiology-nephrology, which together accounted for more than 60% of first quarter revenues – increased by 8.1%.

Sales increased in both the companion animal and livestock segments, the latter reflecting the contributions of the Group's Italian and Indian acquisitions.

*"Vétoquinol's strong performance in the first quarter of 2010 builds on the increases recorded in last two quarter of 2009, confirming the strength of the Group's fundamentals",* stated Matthieu Frechin, Chief Executive Officer of Vétoquinol.

**About Vétoquinol**

*Vétoquinol is an independent veterinary pharmaceutical laboratory serving both the companion and production animal markets. This family-owned group specialized exclusively in animal health is the 10<sup>th</sup> largest laboratory in the world, and more than 80% of Vétoquinol's revenues come from outside France.*

*Vétoquinol engages in the research and development, production and marketing of medical and non-medical products. Vétoquinol has positioned itself in the curative sector, and has developed expertise in three therapeutic fields: anti-infectives, pain/inflammation and cardiology/nephrology.*

*The Group currently distributes its products in more than one hundred countries throughout Europe, Americas and Asia/Pacific, with subsidiaries in 23 different countries and a network of 140 distributor partners. The Company has more than 1,550 employees worldwide.*

**For more information:** [www.vetoquinol.com](http://www.vetoquinol.com).

**OUR BUSINESS, ANIMALS. OUR ADVANTAGE, PEOPLE.**

For more information, contact:

**VETOQUINOL**

Finance department

Marie-Josée AUBRY-ROTA

Tel. : 03 84 62 59 88

[relations.investisseurs@vetoquinol.com](mailto:relations.investisseurs@vetoquinol.com)

**KEIMA COMMUNICATION**

Investor relations

Emmanuel DOVERGNE

Tel. : 01 56 43 44 63

[emmanuel.dovergne@keima.fr](mailto:emmanuel.dovergne@keima.fr)

Media relations

Sibylle DESCAMPS

Tel. : 01 56 43 44 72

[sibylle.descamps@keima.fr](mailto:sibylle.descamps@keima.fr)